Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

FDA Type A Meeting Informs Next Steps for Oral Paclitaxel/Encequidar in Metastatic Breast Cancer

October 12th 2021

Following a Type A meeting with the FDA to discuss deficiencies raised in a complete response letter pertaining to the new drug application for the use of oral paclitaxel encequidar in patients with metastatic breast cancer, the biopharmaceutical company Athenex, Inc. announced that their resources will be redeployed to focus on other studies examining oral paclitaxel.

Sarah Cannon Research Institute Experts Pinpoint Open Clinical Trials in Tennessee

October 11th 2021

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

SERDs, ADCs Broaden Research Avenues Throughout Breast Cancer

October 8th 2021

Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.

Managing ILD: Taking Therapeutic Class Into Account

October 8th 2021

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Approaching the Management of Interstitial Lung Disease

October 8th 2021

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast Cancer

October 6th 2021

Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.

Novel Therapies Shake Up the Spectrum of Breast Cancer Treatment

October 6th 2021

Zahi Mitri, MD, MS, discusses recent advancements made across the breast cancer paradigm and spotlighted key data that led to the integration of novel agents into the armamentariums.

Dr. Burris on the Integration of Sacituzumab Govitecan in Metastatic TNBC

October 5th 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

Sacituzumab Govitecan Significantly Improves HRQoL Vs Physician’s Choice in mTNBC

October 5th 2021

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.

Dr. Hamilton on the Potential Integration of Novel SERDs in ER+/HER2- Breast Cancer

October 4th 2021

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast Cancer

October 4th 2021

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Monitoring Patients for Interstitial Lung Disease

October 1st 2021

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Identifying Risk Factors for Interstitial Lung Disease

October 1st 2021

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Dr. Hurvitz on the Rationale for the coopERA Breast Cancer Trial in ER+/HER2- Breast Cancer

September 29th 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Updated MONALEESA-3 Data Underscore Frontline Efficacy of Ribociclib/Fulvestrant in HR+ Advanced Breast Cancer

September 29th 2021

Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.

Precision Medicine Paves the Way for Advances in Hormone Receptor–Positive Breast Cancer

September 29th 2021

Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.

Dr. Lustberg Discusses Ongoing Research in Breast Cancer

September 28th 2021

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

September 28th 2021

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast Cancer

September 28th 2021

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Frontline Pembrolizumab/Chemo Represents New Standard in Metastatic TNBC With PD-L1 CPS ≥10

September 28th 2021

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.